{"id":121971,"date":"2026-05-04T18:39:13","date_gmt":"2026-05-04T15:39:13","guid":{"rendered":"https:\/\/www.giurgiuveanul.ro\/stiri\/?p=121971"},"modified":"2026-05-04T18:39:13","modified_gmt":"2026-05-04T15:39:13","slug":"pacientii-romanii-care-sufera-de-cancer-tiroidian-avansat-au-de-acum-o-noua-optiune-de-tratament-rambursat","status":"publish","type":"post","link":"https:\/\/www.giurgiuveanul.ro\/stiri\/pacientii-romanii-care-sufera-de-cancer-tiroidian-avansat-au-de-acum-o-noua-optiune-de-tratament-rambursat\/","title":{"rendered":"Pacien\u021bii rom\u00e2nii care sufer\u0103 de cancer tiroidian avansat au de acum o nou\u0103 op\u021biune de tratament rambursat"},"content":{"rendered":"

\"\"<\/a>Ipsen anun\u021b\u0103 includerea \u00een sistemul de rambursare prev\u0103zut de legisla\u021bia din Rom\u00e2nia a unei op\u021biuni terapeutice destinate pacien\u021bilor adul\u021bi cu carcinom tiroidian diferen\u021biat\u00a0 avansat local sau metastazat, refractari sau neeligibili la terapia cu iod radioactiv, care au prezentat progresie \u00een cursul sau dup\u0103 terapiile sistemice administrate anterior1<\/sup><\/em>.<\/p>\n

Aceast\u0103 decizie se adreseaz\u0103 unei categorii de pacien\u021bi cu op\u021biuni terapeutice limitate<\/strong>, pentru care evolu\u021bia bolii impune evaluare medical\u0103 specializat\u0103 \u0219i gestionare \u00een centre cu expertiz\u0103, \u00een conformitate cu indica\u021biile aprobate la nivel european<\/strong> \u0219i cu protocoalele terapeutice aplicabile \u00een Rom\u00e2nia<\/strong>.<\/p>\n

\u201ePentru pacien\u021bii cu forme avansate de boal\u0103 tiroidian\u0103, care nu mai r\u0103spund la abord\u0103rile terapeutice standard, accesul la tratamentul cu cabozantinib prin sistemul de rambursare reprezint\u0103 un element esen\u021bial al \u00eengrijirii. <\/em>Acest pas reflect\u0103 importan\u021ba colabor\u0103rii dintre autorit\u0103\u021bi, comunitatea medical\u0103 \u0219i industrie, \u00een beneficiul pacien\u021bilor cu nevoi medicale neacoperite,\u201d<\/em> a declarat Oana Belinski, Country Lead Ipsen Rom\u00e2nia & Ungaria<\/strong>.<\/p>\n

\u00cen anul 2022, la nivel mondial au fost diagnosticate aproximativ 821.000 de cazuri noi de cancer tiroidian2<\/sup>. Acest\u0103 afec\u021biune reprezint\u0103 cea mai frecvent\u0103 form\u0103 de cancer al sistemului endocrin \u0219i se situeaz\u0103 \u00een top 10 cele mai frecvente tipuri de cancer la nivel global2<\/sup>. Inciden\u021ba estede aproximativ trei ori mai mare la femei dec\u00e2t la b\u0103rba\u021bi, majoritatea cazurilor fiind diagnosticate la persoanele sub v\u00e2rsta de 55 ani2<\/sup>.<\/p>\n

Din totalul tumorilor maligne tiroidiene, carcinomul tiroidian diferen\u021biat reprezint\u0103 aproximativ 90\u201395%3<\/sup>. Dintre acestea, aproximativ 5\u201315% dintre cazuri prezint\u0103 rezisten\u021b\u0103 la tratamentul cu iod radioactiv4<\/sup>.<\/p>\n

Pacien\u021bii care dezvolt\u0103 carcinom tiroidian diferen\u021biat refractar la iod radioactiv se confrunt\u0103 cu o evolu\u021bie nefavorabil\u0103 a bolii, supravie\u021buirea medie estimat\u0103 fiind de aproximativ trei p\u00e2n\u0103 la cinci ani, ceea ce eviden\u021biaz\u0103 existen\u021ba unor nevoi medicale neacoperite \u00een aceast\u0103 categorie de pacien\u021bi5<\/sup>.<\/p>\n

\u00cen contextul Zilei de Con\u0219tientizare a Afec\u021biunilor Tiroidiene (Thyroid Disease Awareness Day)<\/strong>, marcat\u0103 anual la 25 mai<\/strong>, acest demers subliniaz\u0103 importan\u021ba cre\u0219terii nivelului de con\u0219tientizare privind bolile tiroidiene<\/strong>, precum \u0219i a recunoa\u0219terii nevoilor pacien\u021bilor cu forme avansate de boal\u0103<\/strong>, pentru care deciziile terapeutice sunt complexe \u0219i individualizate.<\/p>\n

Despre Ipsen<\/strong><\/p>\n

Ipsen este o companie biofarmaceutic\u0103 global\u0103, concentrat\u0103 pe dezvoltarea de medicamente cu impact transformator<\/strong> \u00een domeniile oncologiei, bolilor rare \u0219i neuro\u0219tiin\u021belor<\/strong>.<\/p>\n

Activit\u0103\u021bile de cercetare \u0219i dezvoltare (R&D)<\/strong> ale Ipsen sunt concentrate pe diferite platforme tehnologice de inova\u021bie,<\/strong> localizate \u00een cadrul unora dintre cele mai importante centre de biotehnologie la nivel mondial (Paris\u2011Saclay, Fran\u021ba; Oxford, Marea Britanie; Cambridge, SUA; Shanghai, China<\/strong>).<\/p>\n

Ipsen comercializeaz\u0103 peste 20 de medicamente \u00een mai mult de 115 \u021b\u0103ri<\/strong>, av\u00e2nd prezen\u021b\u0103 comercial\u0103 direct\u0103 \u00een peste 30 de \u021b\u0103ri,<\/strong> cu aproximativ 5.700 de angaja\u021bi la nivel global<\/strong>.<\/p>\n

 <\/p>\n

Referin\u021be<\/strong><\/p>\n

    \n
  1. European Medicines Agency (EMA) – Cabometyx (cabozantinib) \u2013 Rezumatul Caracteristicilor Produsului.<\/li>\n
  2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer Journal for Clinicians, 2024.<\/li>\n
  3. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26, 1:1\u2013133.<\/li>\n
  4. Schlumberger M, Tahara M, Wirth LJ, et al. New England Journal of Medicine. 2015;372:621\u2013630.<\/li>\n
  5. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma. Journal of Clinical Endocrinology & Metabolism. 2006;91:2892\u20132899.<\/li>\n<\/ol>\n

    CBZ-RO-000325<\/p>\n","protected":false},"excerpt":{"rendered":"

    Ipsen anun\u021b\u0103<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-121971","post","type-post","status-publish","format-standard","hentry","category-breaking-news"],"_links":{"self":[{"href":"https:\/\/www.giurgiuveanul.ro\/stiri\/wp-json\/wp\/v2\/posts\/121971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.giurgiuveanul.ro\/stiri\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.giurgiuveanul.ro\/stiri\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.giurgiuveanul.ro\/stiri\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.giurgiuveanul.ro\/stiri\/wp-json\/wp\/v2\/comments?post=121971"}],"version-history":[{"count":1,"href":"https:\/\/www.giurgiuveanul.ro\/stiri\/wp-json\/wp\/v2\/posts\/121971\/revisions"}],"predecessor-version":[{"id":121973,"href":"https:\/\/www.giurgiuveanul.ro\/stiri\/wp-json\/wp\/v2\/posts\/121971\/revisions\/121973"}],"wp:attachment":[{"href":"https:\/\/www.giurgiuveanul.ro\/stiri\/wp-json\/wp\/v2\/media?parent=121971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.giurgiuveanul.ro\/stiri\/wp-json\/wp\/v2\/categories?post=121971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.giurgiuveanul.ro\/stiri\/wp-json\/wp\/v2\/tags?post=121971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}